{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=135",
    "query": {
      "condition": "Skin Disorders",
      "page": 135
    },
    "page_size": 10
  },
  "pagination": {
    "page": 135,
    "page_size": 10,
    "total_count": 16153,
    "total_pages": 1616,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=136&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=134&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T08:04:21.176Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02296112",
      "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IIIB Melanoma",
        "Stage IIIC Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-01",
      "completion_date": "2021-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296112"
    },
    {
      "nct_id": "NCT03838367",
      "title": "Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "350 mg leronlimab",
          "type": "DRUG"
        },
        {
          "name": "525 mg leronlimab",
          "type": "DRUG"
        },
        {
          "name": "700 mg leronlimab",
          "type": "DRUG"
        },
        {
          "name": "AUC 5 Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Maximum Tolerated Dose (MTD) of leronlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2019-04-22",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Chicago, Illinois",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03838367"
    },
    {
      "nct_id": "NCT03606967",
      "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Personalized Synthetic Long Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2021-04-13",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 30,
      "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03606967"
    },
    {
      "nct_id": "NCT00510367",
      "title": "Primary Breast Cancer Occurring Concomitant With Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 61,
      "start_date": "2001-08-07",
      "completion_date": "2020-07-08",
      "has_results": false,
      "last_update_posted_date": "2020-07-10",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00510367"
    },
    {
      "nct_id": "NCT05488444",
      "title": "A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Navigator Phone Calls",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exit Interview",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-08-25",
      "completion_date": "2023-10-17",
      "has_results": false,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05488444"
    },
    {
      "nct_id": "NCT02722044",
      "title": "Usability of an AI for M923 in Subjects With Moderate to Severe RA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "M923",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autoinjector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Momenta Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-04",
      "completion_date": "2017-02-21",
      "has_results": true,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 7,
      "location_summary": "Detroit, Michigan • Greensboro, North Carolina • Oklahoma City, Oklahoma + 3 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722044"
    },
    {
      "nct_id": "NCT06811909",
      "title": "Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-infected Venous Leg Ulcer",
        "Venous Leg Ulcer",
        "Venous Insufficiency",
        "Venous Stasis",
        "Venous Reflux"
      ],
      "interventions": [
        {
          "name": "BR-AC",
          "type": "OTHER"
        },
        {
          "name": "Standard Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "BioStem Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2025-02-14",
      "completion_date": "2026-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 22,
      "location_summary": "Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06811909"
    },
    {
      "nct_id": "NCT00588887",
      "title": "Total Knee Replacement With Duracon® and Vanguard™ Prostheses",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Degenerative Arthritis",
        "Osteoarthritis",
        "Rheumatoid Arthritis",
        "Knee Arthritis"
      ],
      "interventions": [
        {
          "name": "Duracon®",
          "type": "DEVICE"
        },
        {
          "name": "Vanguard™",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Biomet Orthopedics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2005-06",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 1,
      "location_summary": "Warsaw, Indiana",
      "locations": [
        {
          "city": "Warsaw",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588887"
    },
    {
      "nct_id": "NCT02752893",
      "title": "Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-01-30",
      "completion_date": "2019-04-03",
      "has_results": false,
      "last_update_posted_date": "2020-06-01",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02752893"
    },
    {
      "nct_id": "NCT02557321",
      "title": "PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "PV-10",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Provectus Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-10",
      "completion_date": "2025-04",
      "has_results": false,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-11-17T08:04:21.176Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Lebanon, New Hampshire • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Easton",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557321"
    }
  ]
}